Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
1.830
+0.040 (2.23%)
Nov 26, 2025, 4:00 PM EST - Market closed
Protalix BioTherapeutics Market Cap
Protalix BioTherapeutics has a market cap or net worth of $147.17 million as of November 26, 2025. Its market cap has increased by 64.07% in one year.
Market Cap
147.17M
Enterprise Value
125.98M
1-Year Change
64.07%
Ranking
Category
Stock Price
$1.83
Market Cap Chart
Since December 1, 1998, Protalix BioTherapeutics's market cap has increased from $11.80M to $147.17M, an increase of 1,147.21%. That is a compound annual growth rate of 9.80%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Nov 21, 2025 | 140.70M | 1.66% |
| Dec 31, 2024 | 138.40M | 6.54% |
| Dec 29, 2023 | 129.90M | 87.18% |
| Dec 30, 2022 | 69.40M | 83.11% |
| Dec 31, 2021 | 37.90M | -68.68% |
| Dec 31, 2020 | 121.00M | 148.46% |
| Dec 31, 2019 | 48.70M | 5.64% |
| Dec 31, 2018 | 46.10M | -50.11% |
| Dec 29, 2017 | 92.40M | 107.64% |
| Dec 30, 2016 | 44.50M | -56.29% |
| Dec 31, 2015 | 101.80M | -40.95% |
| Dec 31, 2014 | 172.40M | -52.64% |
| Dec 31, 2013 | 364.00M | -24.96% |
| Dec 31, 2012 | 485.10M | 14.93% |
| Dec 30, 2011 | 422.10M | -47.92% |
| Dec 31, 2010 | 810.50M | 58.46% |
| Dec 31, 2009 | 511.50M | 266.14% |
| Dec 31, 2008 | 139.70M | -45.71% |
| Dec 31, 2007 | 257.30M | 2,552.58% |
| Dec 29, 2006 | 9.70M | -21.77% |
| Dec 30, 2005 | 12.40M | 1,671.43% |
| Dec 31, 2004 | 700.00K | -41.67% |
| Dec 31, 2003 | 1.20M | 300.00% |
| Dec 31, 2002 | 300.00K | -57.14% |
| Dec 31, 2001 | 700.00K | - |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 993.82B |
| Johnson & Johnson | 497.93B |
| AbbVie | 409.68B |
| UnitedHealth Group | 295.56B |
| AstraZeneca | 288.24B |
| Merck & Co. | 262.25B |
| Novartis AG | 248.38B |
| Thermo Fisher Scientific | 224.59B |